世界の神経芽細胞腫治療薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)

GlobalInfoResearchが発行した調査報告書(GIR21JY00001)
◆英語タイトル:Global Neuroblastoma Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
◆商品コード:GIR21JY00001
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2021年7月(※2024年版があります。お問い合わせください。)
◆ページ数:109
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2~3日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

GlobalInfoResearch社の本調査レポートでは、神経芽細胞腫治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経芽細胞腫治療薬の種類別市場規模(化学療法、免疫療法、その他)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・メーカー情報(企業概要、製品概要、販売量、価格、売上):Pfizer、Teva Pharmaceutical、Johnson & Johnson、Bristol-Myers Squibb、United Therapeutics
・メーカー別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:化学療法、免疫療法、その他
・用途別分析2016年-2026年:病院、クリニック、その他
・神経芽細胞腫治療薬の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・神経芽細胞腫治療薬のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・神経芽細胞腫治療薬のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・神経芽細胞腫治療薬の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・神経芽細胞腫治療薬の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
【レポートの概要】

The Neuroblastoma Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Neuroblastoma Drugs size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Neuroblastoma Drugs market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Neuroblastoma Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Chemotherapy
Immunotherapy
Others

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Pfizer
Teva Pharmaceutical
Johnson & Johnson
Bristol-Myers Squibb
United Therapeutics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

【レポートの目次】

1 Market Overview
1.1 Product Overview and Scope of Neuroblastoma Drugs
1.2 Classification of Neuroblastoma Drugs by Type
1.2.1 Overview: Global Neuroblastoma Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Neuroblastoma Drugs Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Immunotherapy
1.2.5 Others
1.3 Global Neuroblastoma Drugs Market by Application
1.3.1 Overview: Global Neuroblastoma Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Neuroblastoma Drugs Market Size & Forecast
1.5 Global Neuroblastoma Drugs Market Size and Forecast by Region
1.5.1 Global Neuroblastoma Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Neuroblastoma Drugs Market Size by Region, (2016-2021)
1.5.3 North America Neuroblastoma Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Neuroblastoma Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Neuroblastoma Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Neuroblastoma Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Neuroblastoma Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroblastoma Drugs Market Drivers
1.6.2 Neuroblastoma Drugs Market Restraints
1.6.3 Neuroblastoma Drugs Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Neuroblastoma Drugs Product and Solutions
2.1.4 Pfizer Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Teva Pharmaceutical
2.2.1 Teva Pharmaceutical Details
2.2.2 Teva Pharmaceutical Major Business
2.2.3 Teva Pharmaceutical Neuroblastoma Drugs Product and Solutions
2.2.4 Teva Pharmaceutical Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Teva Pharmaceutical Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Neuroblastoma Drugs Product and Solutions
2.3.4 Johnson & Johnson Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Neuroblastoma Drugs Product and Solutions
2.4.4 Bristol-Myers Squibb Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 United Therapeutics
2.5.1 United Therapeutics Details
2.5.2 United Therapeutics Major Business
2.5.3 United Therapeutics Neuroblastoma Drugs Product and Solutions
2.5.4 United Therapeutics Neuroblastoma Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 United Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neuroblastoma Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Neuroblastoma Drugs Players Market Share
3.2.2 Top 10 Neuroblastoma Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Neuroblastoma Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Neuroblastoma Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Neuroblastoma Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Neuroblastoma Drugs Revenue Market Share by Application (2016-2021)
5.2 Neuroblastoma Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Neuroblastoma Drugs Revenue by Type (2016-2026)
6.2 North America Neuroblastoma Drugs Revenue by Application (2016-2026)
6.3 North America Neuroblastoma Drugs Market Size by Country
6.3.1 North America Neuroblastoma Drugs Revenue by Country (2016-2026)
6.3.2 United States Neuroblastoma Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Neuroblastoma Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Neuroblastoma Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Neuroblastoma Drugs Revenue by Type (2016-2026)
7.2 Europe Neuroblastoma Drugs Revenue by Application (2016-2026)
7.3 Europe Neuroblastoma Drugs Market Size by Country
7.3.1 Europe Neuroblastoma Drugs Revenue by Country (2016-2026)
7.3.2 Germany Neuroblastoma Drugs Market Size and Forecast (2016-2026)
7.3.3 France Neuroblastoma Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Neuroblastoma Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Neuroblastoma Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Neuroblastoma Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Neuroblastoma Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Neuroblastoma Drugs Market Size by Region
8.3.1 Asia-Pacific Neuroblastoma Drugs Revenue by Region (2016-2026)
8.3.2 China Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8.3.5 India Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Neuroblastoma Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Neuroblastoma Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Neuroblastoma Drugs Revenue by Type (2016-2026)
9.2 South America Neuroblastoma Drugs Revenue by Application (2016-2026)
9.3 South America Neuroblastoma Drugs Market Size by Country
9.3.1 South America Neuroblastoma Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Neuroblastoma Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Neuroblastoma Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Neuroblastoma Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Neuroblastoma Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Neuroblastoma Drugs Market Size by Country
10.3.1 Middle East & Africa Neuroblastoma Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Neuroblastoma Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Neuroblastoma Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Neuroblastoma Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

...

【掲載企業】

Pfizer、Teva Pharmaceutical、Johnson & Johnson、Bristol-Myers Squibb、United Therapeutics

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の神経芽細胞腫治療薬市場2021:メーカー別・地域別・種類別・用途別市場予測(~2026)(Global Neuroblastoma Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。